AMP German Cannabis Group to begin medical cannabis imports from the Netherlands

ERFURT and BERLIN, Germany, July 6th, 2020 – AMP German Cannabis Group Inc. (“AMP” or the “Company”) (CSE: XCX) (FSE: C4T, ISIN: CA00176G1028) announces further to its June 5, 2020 news release The Office of Medical Cannabis (“OMC”), the government organization of the Netherlands for distribution of medical cannabis products, has notified AMP that it will resume exports of EU-GMP medical cannabis to Germany. The OMC will deliver 3,000 grams per month to each German importer due to the high demand and restricted supply currently available for Germany. 

AMP has ordered Bedrocan International branded products to be exported by OMC on a monthly basis beginning July 2020. AMP has received all the required licenses to import irradiated cannabis flowers from the Dutch and German government authorities. 

Dr. Stefan Feuerstein, Director and President of AMP, commented: “All pieces of the puzzle have come together with the start of our first import. We will be booking our first revenue from the sale of our Bedrocan products this month and hope to receive a higher amount from the Netherlands in August 2020. We are also on track to sign a definitive supply agreement with a Canadian supplier and will be adding pharmaceutical distribution partners that focus on medical cannabis exclusively to our distribution network covering Germany. Our next step is to increase import volumes from Canada in conjunction with developing AMP’s medical cannabis brands for the German market.” 

About AMP German Cannabis Group 

AMP German Cannabis Group is licensed to import European Union – Good Manufacturing Practice (EU-GMP) medical cannabis and sell to pharmaceutical distributers or pharmacists directly, the only point-of-sale for medical cannabis to German patients. 

AMP has entered into a non-exclusive distribution agreement for medical cannabis with a leading distributor of pharmaceuticals products to more than 13,000 pharmacies throughout Germany. AMP imports medical cannabis from the Netherlands and beginning the second half of 2020 from Canada. 

To watch the question and answer session with Dr. Stefan Feuerstein recorded on June 29, 2020, click here: (German with English subtitles). 

For more information, please visit: and 


Mr. Alex Blodgett, CEO and Director 

Telephone: +1 236-833-1602 


AMP social media links: 

• Twitter: 

• LinkedIn: 

• Facebook: 

Media Kit: 

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. 

This news release contains forward-looking statements that are based on the Company’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business plans and milestones and the timing thereof. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. 

SOURCE AMP German Cannabis Group Inc.